| Quote
: |
李军,刘存勇.中西医结合治疗对帕金森患者生活质量的影响及临床疗效观察[J].湖南中医药大学学报英文版,2017,37(7):789-791.[Click to copy
] |
|
| |
|
|
| This paper
：Browser 1847times Download 479times |
| 中西医结合治疗对帕金森患者生活质量的影响及临床疗效观察 |
| 李军,刘存勇 |
| (北京市垂杨柳医院, 北京 100022) |
| 摘要: |
| 目的 观察健脾温肾方对腹泻型肠易激综合征的临床疗效及对血清T淋巴细胞亚群的影响。方法 将符合纳入标准的患者59例随机分为2组，其中对照组29例，治疗组30例，对照组给予匹维溴铵治疗，治疗组在对照组的基础上给予健脾温肾方治疗，2组患者疗程均为4周，并随访8周。分别观察2组治疗前后临床症状积分、大便Bristol评分、生活质量评分（IBS-QOL、SF-36）、血清T淋巴细胞亚群及随访的复发率。结果 对照组总有效率为89.7%，治疗组为93.3%，两组比较差异具有统计学意义（P<0.05）。两组治疗后Bristol评分明显降低（P<0.05），治疗后组间比较，差异具有统计学意义（P<0.05）；IBS-QOL、SF-36评分明显升高（P<0.05），治疗后组间比较，差异具有统计学意义（P<0.05）；CD4+、CD4+/CD8+水平与治疗前比较均明显升高（P<0.05），治疗后组间比较，差异具有统计学意义（P<0.05）；CD8+水平与治疗前比较均明显升高（P<0.05），治疗后组间比较，差异具有统计学意义（P<0.05）。对照组随访复发率为34.5%，治疗组为10%，对照组复发率明显高于治疗组（P<0.05）。结论 健脾温肾方能显著缓解IBS-D患者临床症状及改善大便性质及生活质量，提高患者的免疫功能，复发率低，且无明显不良反应。 |
| 关键词: 腹泻型肠易激综合征 健脾温肾方 临床疗效 T淋巴细胞亚群 |
| DOI：10.3969/j.issn.1674-070X.2017.07.024 |
| Received:September 20, 2016 |
| 基金项目: |
|
| Influence of Integrated Traditional Chinese and Western Medicine on the Qualityof Life in Patients with Parkinson |
| LI Jun,LIU Cunyong |
| (Chuiyangliu Hospital, Beijing 100022, China) |
| Abstract: |
| Objective To investigate the clinical effect and the quality of life of Peiyuan Tongnao capsule combined with conventional Western medicine benserazide and piribedil on patients with parkinson. Methods 68 cases of patients with Parkinson's disease treated in our hospital from June 2014 to June 2016 were randomly divided into the control group and the observation group, 34 cases in each group. The control group was treated with Yiduobasi hydrazine and piribedil, the observation group was added with Peiyuan Tongnao capsule on the basis of control group. The UPDRS efficacy, TCM syndrome score and the daily living ability of ADL score after the treatment were compared. Results After treatment, the ADL score of two groups were all higher than before treatment (P<0.05), the scores of the treatment group were higher than those of the control group at the first four weeks, the difference was statistically significant (P<0.05). The total score of UPDRS 85.3% of the treatment group was higher than that 61.8% of the control group, and the difference was statistically significant (P<0.05). The effect of tremor, rigidity, insomnia, constipation, sweating symptoms in treatment group was significantly higher than those of the control group (P<0.05). Conclusion Peiyuan Tongnao capsule combined with benserazide and piribedil could effectively improve the clinical symptoms of patients with Parkinson's disease, improve the quality of life. |
| Key words: Parkinson's disease Peiyuan Tongnao capsule benserazide piribedil quality of life integrated traditional Chinese and Western |
|
二维码（扫一下试试看！） |
|
